Highlights in ADA 2021 for Diabetes Technologies and Therapeutics
The American Diabetes Association (ADA) Annual Meetings provide great opportunities to the whole diabetes community for networking, collaboration, and learning updates in the field of diabetes. Virtual meeting amidst pandemic was a huge success. Halis Kaan Akturk summarized all study outcomes presented at ADA annual meet under the title “Highlights in ADA 2021 for Diabetes Technologies and Therapeutics”. The gist of his article is given below:
Objective:
To highlight study findings that will be beneficial in real-life users with diabetes.
Method:
Summary of studies reporting positive results in diabetes technologies, continuous glucose monitoring, automated insulin delivery systems, and newer therapeutics is provided.
Findings:
A prospective, multi-center study was conducted by Garg et al. to evaluate the safety and accuracy of the next-generation Eversense CGM System and also next-generation Eversense sensor, modified with sacrificial boronic acid (SBA). Minimum adverse events were reported related to the procedure while both sensors were tolerated well. This new system increased the use of implantable CGM up to 180 days with more accuracy.
Many studies reported results of Omnipod 5, an automated insulin delivery device. A swimming study using Omnipod 5 reports that there was no difference in CGM metrics such as time in range and time in hypoglycemia 2-hour before and during the swimming. Studies have shown participants transitioning directly from multiple daily injections in the pivotal study of the Omnipod 5 System. Many studies reported a significant decrease in HbA1c with Omnifod 5 system intervention.
Fuchs et al. conducted a study to assess the safety and efficacy of the CamAPS FX hybrid closed loop system in children. The study reports that the time in range and HbA1c improvement were significant after six months of CamAPS FX use.
As per the study conducted by Shah et al., the overlap of insulin degludec and insulin pump in the first 48 hours results in better glycemic control without increasing hypoglycemia in adults with Type 1 diabetes.
A double-blind, randomized, placebo-controlled trial of Volagidemab, a Human Glucagon Receptor Antagonist, as adjunctive therapy in Type 1 diabetes was conducted by Pettus et al. Findings report a significant decrease in HbA1c and insulin use with volagidemab. There was an intermittent increase in ALT and blood pressure that returned to baseline after treatment.
Image Credit : Business photo created by pressfoto – www.freepik.com